PMGC Holdings (ELAB) Interest Expenses (2022 - 2026)
PMGC Holdings (ELAB) posted Interest Expenses of $2.8 million for Q1 2026, up 1049.9% sequentially from $243241.0 in Q4 2025, and up 26604.52% YoY from N/an in Q1 2025.
PMGC Holdings (ELAB) Interest Expenses (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Interest Expenses for 5 years, with the latest figure at $2.8 million in Q1 2026.
- Quarterly Interest Expenses rose 26604.52% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 26604.52% YoY) and the FY2025 annual result came in at $1.0 million, down 69.1% from the prior year.
- Interest Expenses improved to $2.8 million in Q1 2026 per ELAB's latest filing, from $243241.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $269.5 million in Q3 2023 and troughed at -$2.6 million in Q4 2022.
- A 5-year average of $18.2 million and a median of $188675.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 43338.01% in 2024, then tumbled 100.0% in 2025.
- Over 5 years, Interest Expenses stood at -$2.6 million in 2022, then surged by 100.06% to $1639.0 in 2023, then soared by 43338.01% to $711949.0 in 2024, then plunged by 65.83% to $243241.0 in 2025, then soared by 1049.9% to $2.8 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $2.8 million, $243241.0, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 582,241.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.80 Mn |
| Mar 31, 2026 | 2.80 Mn |
| Dec 31, 2025 | 243,241.00 |
| Dec 31, 2025 | 243,241.00 |
| Sep 30, 2025 | 1.14 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 2.00 |
| Jun 30, 2025 | 2.00 |
| Mar 31, 2025 | 10,474.00 |
| Mar 31, 2025 | 10,474.00 |
| Dec 31, 2024 | 711,949.00 |
| Dec 31, 2024 | 711,949.00 |
| Sep 30, 2024 | 684,576.00 |
| Sep 30, 2024 | 684,576.00 |
| Jun 30, 2024 | 148,245.00 |
| Jun 30, 2024 | 148,245.00 |
| Mar 31, 2024 | 188,675.00 |
| Mar 31, 2024 | 188,675.00 |
| Dec 31, 2023 | 1,639.00 |
| Dec 31, 2023 | 1,639.00 |